CD86 and melanoma: Notably, CD86 has shown higher affinity for binding to CTLA‐4 than that to CD28 (14), indicating the significance of CD86 in immunotherapeutic strategies based on CTLA-4 blockades, which have shown promising effects in treating solid tumors like melanoma (15) and mesothelioma (16) in clinical trials.